Rolf T. Hansen, PhD

Transitioning Patients to Long-Acting Injectable Antipsychotics: Attitudes and Perceptions of US Clinicians Based on a Hypothetical Case (Results From the DECIDE Survey)

This analysis presents the opinions of US-practicing psychiatric clinicians on a hypothetical case where a psychiatrist introduces the topic of transitioning to a long-acting injectable a...

Rolf T. Hansen , PhD;

10/26/2023

Analysis of AIMS Global Judgment Components (Items 8–10) in Patients With TD: Results From the ARM-TD and AIM-TD Studies

Background: Tardive dyskinesia (TD) is a debilitating, often-irreversible hyperkinetic movement disorder that impairs patients’ abilities to perform daily activities. Deutetrabenazine was...

Amanda Wilhelm , PhD;

Hadas Barkay , PhD;

Rolf T. Hansen , PhD;

Juha-Matti Savola , MD, PhD;

Maria Wieman , MPH;

Nicholas Gross , MS;

11/22/2019

Understanding the Use of Long-Acting Injectable Antipsychotic Agents in Schizophrenia: A 2022 Survey of US Psychiatrists, Nurse Practitioners, and Physician Associates

Abstract: Background: Treatment with long-acting injectable antipsychotic agents (LAIs) has been shown to improve outcomes in schizophrenia; however, many healthcare providers continue to...

Kelsey Hogan ;

Rolf T. Hansen , PhD;

01/19/2023

Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotics: A Survey of US Psychiatric Clinicians (Results from the DECIDE Survey)

Clinician perspectives on the use of long-acting injectable antipsychotics (LAIs) for the treatment of schizophrenia are central to understanding real-world barriers to LAI use. In this s...

Rolf T. Hansen , PhD;

10/26/2023